Liver cancer – New and effective treatment with Toripalimab and HAIC Plus Lenvima
Background – New option for Liver cancer Hepatic Arterial Infusion Chemotherapy, HAIC, is a medical procedure that delivers chemotherapy directly to the liver and widely
Gastric and GEJ cancers – Keytruda to HER2+ patients, improves outcomes
Background The first findings of KEYNOTE-811, an ongoing, global phase III trial, found that the addition of Keytruda to Herceptin plus chemotherapy for first-line treatment
Pancreatic Cancer – Nadunolimab brings positive results
Background Pancreatic cancer is an aggressive type of cancer with very little treatment options that are mostly disappointing especially in the advanced stages of disease,
Glioblastoma and all gliomas – Tafinlar plus Mekinist, a durable benefit
Background – Glioblastoma and BRAF BRAFV600E mutations are rarely encountered in adult glioblastoma with an incidence ranging from less than 1% to 8%. But young
Lung Cancer Treated with Electric Fields – Strongly Positive Results
Background Interim analysis of the phase 3 LUNAR trial led to a recommendation to reduce the number of lung cancer patients required. This recommendation is
Glioblastoma – Just diagnosed? planned for surgery?
Background A study published in the prestigious JAMA Oncology (The Journal of the American Medical Association) confirmed an association between maximal resection of contrast-enhanced tumor
Small Cell Lung Cancer – Fast Track Designation to Onivyde
Background The FDA granted fast track designation to Onivyde injection for the treatment of patients with Small Cell Lung Cancer, SCLC, who progressed following a
Ovarian Cancer – Fast Track Designation to GEN-1 Immunotherapy
Background Women with advanced ovarian cancer have limited treatment options in the standard of care and therefore they have much better chances and hope in
What is a “Compassionate Drug”?
A Compassionate Drug is a new drug. So, first of all one needs to know that a Compassionate Drug is a new drug. The newest
Gastric Cancer – Bemarituzumab Plus Chemo Improves Outcomes
Background Gastric cancer has a new target to attack: FGFR2b. Anew drug, “Bemarituzumab”, targets FGFR2b. When Bemarituzumab was given with chemotherapy, the combination postponed the
Colorectal cancer – Onvansertib, a Novel Oral PLK1 Inhibitor
Background On average, KRAS is mutated in approximately 50% of patients with colorectal cancer. Chemotherapy in combination with targeted drugs is standard of care option
